Compare UL & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UL | VRTX |
|---|---|---|
| Founded | 1930 | 1989 |
| Country | United Kingdom | United States |
| Employees | 96092 | N/A |
| Industry | Package Goods/Cosmetics | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.3B | 115.7B |
| IPO Year | N/A | 2006 |
| Metric | UL | VRTX |
|---|---|---|
| Price | $57.58 | $445.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $539.69 |
| AVG Volume (30 Days) | ★ 3.8M | 1.2M |
| Earning Date | 03-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 4.02 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | $2.53 | $10.79 |
| Revenue Next Year | $3.78 | $10.47 |
| P/E Ratio | ★ $14.29 | $110.18 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $54.75 | $362.50 |
| 52 Week High | $74.98 | $509.98 |
| Indicator | UL | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 55.36 |
| Support Level | $56.64 | $429.02 |
| Resistance Level | $58.66 | $461.66 |
| Average True Range (ATR) | 0.80 | 9.70 |
| MACD | 0.07 | 1.14 |
| Stochastic Oscillator | 73.68 | 79.53 |
Unilever is a diversified beauty, wellbeing, and personal care (51% of 2025 sales by value), homecare (23%), and packaged food (26%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.